Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down [Yahoo! Finance]
Bio-Rad Laboratories, Inc. Class A (BIO)
Last bio-rad laboratories, inc. class a earnings: 2/13 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
bio-rad.com/en-us/corporate/investor-relations
Company Research
Source: Yahoo! Finance
The quarter's adjustments eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, Restructuring costs, gains/losses from the change in the fair market value of equity securities and gains/losses on equity-method investments. The company's GAAP EPS was $13.45 per share in the first quarter compared with GAAP earnings of $2.32 in the year-ago quarter. Revenues in Detail Revenues of $610.8 million in the first quarter missed the Zacks Consensus Estimate by 0.2%. The figure dropped 9.8% from the year-ago quarter's levels (down 9.6% at the constant exchange rate or CER). Segmental Analysis Sales in the Life Science segment in the first quarter totaled $241.7 million, down 25.3% year over year and 25.2% at CER. The currency-neutral year-over-year sales decline was broad-based and was primarily due to weakness in the biotech and biopharma end markets and the economic environment in China. Net sales in the Clinical Diagnostics segment
Show less
Read more
Impact Snapshot
Event Time:
BIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIO alerts
High impacting Bio-Rad Laboratories, Inc. Class A news events
Weekly update
A roundup of the hottest topics
BIO
News
- Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at UBS Group AG from $420.00 to $385.00. They now have a "buy" rating on the stock.MarketBeat
- Bio-Rad Reports First-Quarter 2024 Financial ResultsBusiness Wire
- Molecular Weight Marker Market Forecast Report 2019-2029, Featuring Bio-Rad Laboratories, Merck, New England Biolabs, Promega, QIAGEN, VWR, Takara Bio, HiMedia Laboratories and GeneDireX [Yahoo! Finance]Yahoo! Finance
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceBusiness Wire
- Liquid Handling Systems Market Size Worth $8.07 billion by 2031 at a CAGR of 7.8%: Straits Research [Yahoo! Finance]Yahoo! Finance
BIO
Earnings
- 5/7/24 - Beat
BIO
Sec Filings
- 5/9/24 - Form SD
- 5/8/24 - Form S-8
- 5/8/24 - Form 10-Q
- BIO's page on the SEC website